Search research articles
Contact Us
Filters
Showing results (51-60 of 106) with videos related to
Page
of 11
Sort By:
Plos One
|
October 8, 2015
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
Roland Morley, Alison Cardenas, Peter Hawkins, et al.
Molecular Cancer Therapeutics
|
March 29, 2013
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors
Elicia Penuel, Congfen Li, Vaishali Parab, et al.
Neuro-Oncology
|
May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Holger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Plos Genetics
|
March 6, 2013
Hepatocyte growth factor, a determinant of airspace homeostasis in the murine lung
Carla Calvi, Megan Podowski, Armando Lopez-Mercado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2013
Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development
Hong Xiang, Brendan C Bender, Arthur E Reyes, et al.
Analytical Chemistry
|
September 9, 2022
Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach
Lingyao Meng, Emily W Chan, Carl Ng, et al.
Cell Reports
|
August 16, 2018
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation
Ryan Raisner, Samir Kharbanda, Lingyan Jin, et al.
Cancer Research
|
November 16, 2011
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition
Klaus P Hoeflich, Mark Merchant, Christine Orr, et al.
Cancer Discovery
|
December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790M
Ho-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Cell Reports
|
April 4, 2019
Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation
Denise E de Almeida Nagata, Eugene Y Chiang, Suchit Jhunjhunwala, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 106) with videos related to
Sort By:
Page
of 11
Plos One
|
October 8, 2015
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
Roland Morley, Alison Cardenas, Peter Hawkins, et al.
Molecular Cancer Therapeutics
|
March 29, 2013
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors
Elicia Penuel, Congfen Li, Vaishali Parab, et al.
Neuro-Oncology
|
May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Holger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Plos Genetics
|
March 6, 2013
Hepatocyte growth factor, a determinant of airspace homeostasis in the murine lung
Carla Calvi, Megan Podowski, Armando Lopez-Mercado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2013
Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development
Hong Xiang, Brendan C Bender, Arthur E Reyes, et al.
Analytical Chemistry
|
September 9, 2022
Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach
Lingyao Meng, Emily W Chan, Carl Ng, et al.
Cell Reports
|
August 16, 2018
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation
Ryan Raisner, Samir Kharbanda, Lingyan Jin, et al.
Cancer Research
|
November 16, 2011
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition
Klaus P Hoeflich, Mark Merchant, Christine Orr, et al.
Cancer Discovery
|
December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790M
Ho-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Cell Reports
|
April 4, 2019
Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation
Denise E de Almeida Nagata, Eugene Y Chiang, Suchit Jhunjhunwala, et al.
Page
of 11